United
States breast cancer therapeutics market is expected to grow at an impressive
rate during the forecast period. The rising incidence of breast cancer,
improvements in cancer biology and pharmacology that support treatment
development, rising R&D investment, the introduction of several diagnostic
and screening programs, and favorable insurance and reimbursement policies
contribute to the growth of the market.
Over
the past few decades, the incidence of breast cancer has been steadily rising,
primarily because of aging population and altering lifestyles. The prevalence
of breast cancer is also increasing as a result of hereditary and environmental
factors, including obesity, sedentary behavior, and exposure to specific
chemicals. The market for breast cancer therapeutics is expanding as a result
of the rise in the incidence of breast cancer, which is driving the demand for
more effective and cutting-edge treatments.
Due
to the vast number of therapeutics in development, the market for breast cancer
therapeutics is predicted to expand significantly over the next few years.
Immune checkpoint inhibitors, antibody-drug conjugates, and bispecific
antibodies are a few of the innovative medicines and therapy approaches that
are currently being created for the treatment of breast cancer. The United
States breast cancer therapeutics market will grow even more as a result of the
effective development and approval of these treatments.
In
the United States, around 264,000 cases of breast cancer are discovered in
women each year and 2,400 cases have been reported in men, according to the
Centers for Disease Control and Prevention (CDC). In the United States, breast
cancer claims the lives of over 42,000 women and 500 men annually.
However,
several unfavorable drug side effects and the high price of
therapeutics have negatively impacted the growth of the United States breast
cancer therapeutics market. Concerns have been stated regarding the increased
risk of chronic & acute consequences among breast cancer patients due to
the negative effects of chemotherapy. These chemotherapy patients typically
suffer from problems such as heart toxicity, pneumonitis, arm lymphedema,
neuropathy, and skin problems.
Additionally,
the adjuvant therapy can cause neutropenia, radiation dermatitis, fatigue, and
other side effects. The numerous side effects connected with breast cancer treatments
may restrict the use of therapy and impede market expansion.
In
the treatment of breast cancer, immunotherapy, a new area in oncology, has
produced encouraging results. Immunotherapies, including immune checkpoint
inhibitors, have been demonstrated to be helpful in treating some forms of
breast cancer, which, in turn, will increase their use in the coming years.
Immune checkpoint inhibitors function by provoking the immune system to combat
cancer cells. The United States breast cancer therapeutics market is
anticipated to grow during the next few years due to the rising use of
immunotherapies.
The
goal of precision medicine is to determine the specific genetic alterations
that are causing cancer in patients. This is done using genetic testing and
other molecular diagnostic methods. As a result, more specialized and tailored
treatment alternatives can be created. The development of novel, more potent
breast cancer treatments is anticipated to be fueled by the increased emphasis
on precision medicine.
A
healthcare strategy known as patient-centric care puts the patient's unique
requirements, preferences, and values first. More patient-friendly breast
cancer therapies are anticipated to be developed as the importance placed on
patient-centered care increases. For instance, the creation of at-home oral
medicines is anticipated to enhance patients' quality of life by lowering the
frequency of hospital visits.
Scorpion
Therapeutics, Inc. (Scorpion), a cutting-edge clinical-stage oncology company
that is redefining the frontier of precision medicine through its Precision
Oncology 2.0 strategy, announced that the first patient has been dosed in a
Phase 1/2 first-in-human dose escalation and expansion clinical trial
evaluating STX-478, Scorpion's highly unique, allosteric, and central
nervous-system (CNS) penetrant mutant phosphoinositide-3-kinase alpha
(“PI3Kα”), for the treatment of HR+/HER2- breast cancer and other solid tumors.
In the Phase 1/2 clinical trial, STX-478 will be examined both alone and in
combination with other approved drugs in patients with HR+/HER2- breast cancer.
These solid tumors include head and neck squamous cell carcinoma (HNSCC), gynecological
and breast cancers, and others.
Improvements
in Cancer Biology and Pharmacology that Support Treatment Development
The
United States breast cancer therapeutics market is expected to grow in the
coming years due to advancements in cancer biology and pharmacology that assist
therapy development. New and more potent treatments for breast cancer are being
created as scientists and researchers continue to understand the biology and
pharmacology of cancer. The development of personalized medicine, combination
therapy, targeted therapies, and improvements in drug delivery are a few of the
developments in cancer biology and pharmacology which are propelling the
market's expansion.
An
innovative targeted therapy for difficult-to-treat advanced breast tumors was authorized
by the Food and Drug Administration. Research and campaigns from the lab of
Donald McDonnell, PhD, Glaxo-Wellcome Distinguished Professor of Molecular
Cancer Biology at the Department of Pharmacology and Cancer Biology, were vital
to its development. The entirely novel medication elacestrant occupies an
important void in the market. It is the first and only medication authorized
particularly to treat breast tumors with mutations in the ESR1 estrogen
receptor, which are resistant to conventional endocrine therapy. According to a
press statement from the drug's creator, these mutations can be found in up to
40% of advanced or metastatic breast tumors that test positive for the estrogen
receptor but negative for the HER2 receptor. Thus, the United States breast
cancer therapeutics market is anticipated to grow due to the enhancements in
cancer biology and pharmacology.
Download Free Sample Report
Growing
Incidences of Breast Cancer
In
the United States, breast cancer is one of the most prevalent cancers that
affect women, and its prevalence has increased recently. Numerous factors, such
as changes in lifestyle, aging population, and inheritance have led to an
increase in the incidence of breast cancer. The likelihood of acquiring breast
cancer has increased as sedentary lifestyles and unhealthy diets have become
increasingly common. The risk of acquiring breast cancer also rises with
population aging.
Additionally,
more women are undergoing screening and diagnosis due to the growing awareness
of breast cancer and the value of early detection, which is fueling the demand
for breast cancer therapeutics. Treatment of breast cancer requires early
detection, and the availability of efficient therapies can greatly enhance
patient outcomes.
The
United States breast cancer therapeutics market is anticipated to grow to meet
the rising need for effective treatments as the incidence of breast cancer will
increase in the coming years.
Introduction
of Several Diagnostic and Screening Programs
Programs
for diagnosis and screening are essential for identifying breast cancer at an early
stage. The key to successfully treat breast cancer is early detection. The
United States has implemented a number of diagnostic and screening initiatives
to boost breast cancer's early detection rate. Mammography, clinical breast
examination, breast self-examination, and genetic testing are among these programs.
The
most used breast cancer screening method is mammography. A low-dose x-ray can
identify breast cancer early or before any symptoms manifest. A healthcare
expert physically examines breasts during a clinical breast exam. Women can
perform a breast self-examination on their own to find any anomalies in their
breasts. Women who have inherited DNA mutations that enhance their risk of
breast cancer are found through genetic testing.
In
the next years, the market for breast cancer medicines in the United States is
anticipated to expand in response to the rising need for efficient treatments,
which is being influenced by the implementation of numerous diagnostic and
screening programs. The outcomes for breast cancer patients can be considerably
improved by the availability of efficient treatments. The quality of life and
outcomes for breast cancer patients are expected to be significantly improved
by the United States breast cancer therapeutics market during the forecast
period.
Market Segmentation
The
United States breast cancer therapeutics market can be segmented by therapy, end
user, and region. By therapy, the United States
breast cancer therapeutics market can be segmented into chemotherapy, hormone
therapy, immunotherapy, targeted therapy, and others. Based on chemotherapy,
the United States breast cancer therapeutics market is divided into anthracyclines,
taxanes, antimetabolites, and others. Based on hormone therapy, the United
States breast cancer therapeutics market is divided into selective estrogen
receptor modulators, aromatase inhibitors, and others. Based on targeted
therapy, the United States breast cancer therapeutics market is divided into monoclonal
antibodies, tyrosine kinase inhibitor, herceptin, and others. Based on end user,
the United States breast cancer therapeutics market is divided into hospitals,
specialty clinics, ambulatory surgical centers, and others.
Market Players
AstraZeneca PLC, Eli Lilly
and Company, Genentech, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis
International AG, Pfizer Inc., Seattle Genetics, Inc. are among others some of the leading companies operating
in the United
States breast cancer therapeutics market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, Volume Units and
CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast, Volume forecast company share, competitive
landscape, growth factors, and trends
|
|
Segments covered
|
By Therapy
By End User
|
|
Regional scope
|
Northeast Region; Midwest Region; South Region; West Region
|
|
Key companies profiled
|
AstraZeneca PLC, Eli Lilly and Company,
Genentech, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International
AG, Pfizer Inc., Seattle Genetics, Inc.
|
|
Customization scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet
your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report Scope:
In this report, United States
Breast cancer therapeutics market has been segmented into following categories,
in addition to the industry trends which have also been detailed below:·
United
States Breast Cancer Therapeutics Market, By Therapy
o
Chemotherapy
o
Hormone Therapy
o
Immunotherapy
o
Targeted Therapy
o
Others
·
United States Breast Cancer
Therapeutics Market, By Chemotherapy Drugs
o
Anthracyclines
o
Taxanes
o
Antimetabolites
o
Others
·
United States Breast Cancer
Therapeutics Market, By Hormone Therapy
o
Selective Estrogen Receptor Modulators
o
Aromatase Inhibitors
o
Others
·
United States Breast Cancer
Therapeutics Market, By Targeted Therapy
o Monoclonal Antibodies
o Tyrosine Kinase Inhibitor
o Herceptin
o Others
·
United States Breast Cancer
Therapeutics Market, By End User
o Hospitals
o Specialty Clinics
o Ambulatory Surgical Centers
o Others
Competitive Landscape
Company Profiles: Detailed analysis of the
major companies present in the United States breast cancer therapeutics market
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
United States Breast Cancer Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]